Page last updated: 2024-10-30

metformin and Carcinoma, Transitional Cell

metformin has been researched along with Carcinoma, Transitional Cell in 4 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.

Research Excerpts

ExcerptRelevanceReference
" Cox regression models addressed the association of diabetes mellitus (DM) and metformin use with disease recurrence, cancer-specific mortality, and any-cause mortality."7.80Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. ( Babjuk, M; Bachmann, A; Chrystal, J; Crivelli, JJ; Faison, T; Fajkovic, H; Karakiewicz, PI; Kluth, L; Lotan, Y; Rieken, M; Scherr, DS; Shariat, SF; Sun, M; Xylinas, E, 2014)
" Cox regression models addressed the association of diabetes mellitus (DM) and metformin use with disease recurrence, cancer-specific mortality, and any-cause mortality."3.80Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. ( Babjuk, M; Bachmann, A; Chrystal, J; Crivelli, JJ; Faison, T; Fajkovic, H; Karakiewicz, PI; Kluth, L; Lotan, Y; Rieken, M; Scherr, DS; Shariat, SF; Sun, M; Xylinas, E, 2014)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Fiala, O1
Buti, S1
Takeshita, H1
Okada, Y1
Massari, F1
Palacios, GA1
Dionese, M1
Scagliarini, S1
Büttner, T1
Fornarini, G1
Myint, ZW1
Galli, L1
Souza, VC1
Pichler, R1
De Giorgi, U1
Quiroga, MNG1
Gilbert, D1
Popovic, L1
Grande, E1
Mammone, G1
Berardi, R1
Crabb, SJ1
Molina-Cerrillo, J1
Freitas, M1
Luz, M1
Iacovelli, R1
Calabrò, F1
Tural, D1
Atzori, F1
Küronya, Z1
Chiari, R1
Campos, S1
Caffo, O1
Fay, AP1
Kucharz, J1
Zucali, PA1
Rinck, JA1
Zeppellini, A1
Bastos, DA1
Aurilio, G1
Mota, A1
Trindade, K1
Ortega, C1
Sade, JP1
Rizzo, M1
Vau, N1
Giannatempo, P1
Barillas, A1
Monteiro, FSM1
Dauster, B1
Cattrini, C1
Nogueira, L1
de Carvalho Fernandes, R1
Seront, E1
Aceituno, LG1
Grillone, F1
Cutuli, HJ1
Fernandez, M1
Bassanelli, M1
Roviello, G1
Abahssain, H1
Procopio, G1
Milella, M1
Kopecky, J1
Martignetti, A1
Messina, C1
Caitano, M1
Inman, E1
Kanesvaran, R1
Herchenhorn, D1
Santini, D1
Manneh, R1
Bisonni, R1
Zakopoulou, R1
Mosca, A1
Morelli, F1
Maluf, F1
Soares, A1
Nunes, F1
Pinto, A1
Zgura, A1
Incorvaia, L1
Ansari, J1
Zabalza, IO1
Landmesser, J1
Rizzo, A1
Mollica, V1
Sorgentoni, G1
Battelli, N1
Porta, C1
Bellmunt, J1
Santoni, M1
Rieken, M2
Xylinas, E2
Kluth, L2
Trinh, QD1
Lee, RK1
Fajkovic, H2
Novara, G1
Margulis, V1
Lotan, Y2
Martinez-Salamanca, JI1
Matsumoto, K1
Seitz, C1
Remzi, M1
Karakiewicz, PI2
Scherr, DS2
Briganti, A1
Kautzky-Willer, A1
Bachmann, A2
Shariat, SF2
Crivelli, JJ1
Chrystal, J1
Faison, T1
Sun, M1
Babjuk, M1
Nayan, M1
Bhindi, B1
Yu, JL1
Hermanns, T1
Mohammed, A1
Hamilton, RJ1
Finelli, A1
Jewett, MA1
Zlotta, AR1
Fleshner, NE1
Kulkarni, GS1

Other Studies

4 other studies available for metformin and Carcinoma, Transitional Cell

ArticleYear
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
    Cancer immunology, immunotherapy : CII, 2023, Volume: 72, Issue:11

    Topics: Carcinoma, Transitional Cell; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Pro

2023
Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2014, Volume: 40, Issue:1

    Topics: Aged; Carcinoma, Transitional Cell; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycem

2014
Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
    Urologic oncology, 2014, Volume: 32, Issue:1

    Topics: Aged; Carcinoma, Transitional Cell; Cause of Death; Cystectomy; Diabetes Mellitus; Female; Follow-Up

2014
The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
    Urologic oncology, 2015, Volume: 33, Issue:9

    Topics: Aged; Carcinoma, Transitional Cell; Cohort Studies; Cystectomy; Diabetes Mellitus; Disease-Free Surv

2015